7210 Wareham Drive, Tampa, FL 33647
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at […]
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0
Medifast Reports Q4 and Full Year 2024 Results Read More »
Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed
Conflicts in Trump Administration For Support of GLP-1 Meds Read More »
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the
The Party Is Almost Over for GLP-1 Compounders Read More »
Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to
Weight Watchers Reports 3rd Quarter Results Read More »
Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672
Medifast Reports 3rd Quarter Results Read More »
Oct. 8, 2024 WW announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions. The new offering, starting at $129, enhances the Company’s holistic weight management program, which includes behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global Weight Watchers community. This
Weight Watchers Adds Compounded Meds Read More »
August 1, 2024 In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards
Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s Read More »
August 1, 2024 Management reported that: “WeightWatchers has the right strategy to return the business to growth. With a rapidly changing landscape, we are taking decisive actions to navigate through this environment and completely reimagining how we operate,” said Sima Sistani, the Company’s CEO. “We are executing a significant streamlining of our operational structure, to
Weight Watchers Reports Q2 Results Read More »
April 29, 2024 Management said that: “Our new model is highly differentiated from competitors, with a holistic approach including our habit-based and Coach guided solution along with nutrition products and community support. It will be supported by a reimagined framework for customer acquisition, with a new company-led national marketing campaign, enhancing both awareness of the
Medifast Reports Q1 2024 Results Read More »